These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20124396)

  • 1. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
    Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
    Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.
    Vourvahis M; Davis J; Wang R; Layton G; Choo HW; Chong CL; Tawadrous M
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4303-9. PubMed ID: 22644026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
    Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
    Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.
    Vourvahis M; Wang R; Gruener DM; Bruce RD; Haider S; Tawadrous M
    Drug Alcohol Depend; 2012 Nov; 126(1-2):183-8. PubMed ID: 22682979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
    Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
    Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
    Davis J; Langdon G; Layton G; Chong CL; Ndongo MN; Vourvahis M
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1567-72. PubMed ID: 22527351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies.
    Sigafoos JF; Bowers GD; Castellino S; Culp AG; Wagner DS; Reese MJ; Humphreys JE; Hussey EK; O'Connor Semmes RL; Kapur A; Tao W; Dobbins RL; Polli JW
    Drug Metab Dispos; 2012 Nov; 40(11):2090-101. PubMed ID: 22851617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.
    Vourvahis M; Banerjee S; LaBadie R; Gore D; Mayer H
    Antimicrob Agents Chemother; 2010 May; 54(5):2209-11. PubMed ID: 20160047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers.
    Davis J; Hackman F; Ndongo MN; Choo H; Lewis D; Tawadrous M; Goodrich J; Langdon G
    Clin Ther; 2010 Oct; 32(11):1889-95. PubMed ID: 21095483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.
    Vourvahis M; Langdon G; Layton G; Labadie RR; Choo HW; Ndongo MN; Davis J
    J Acquir Immune Defic Syndr; 2012 May; 60(1):24-32. PubMed ID: 22517413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans.
    Kumar S; Tan EY; Hartmann G; Biddle Z; Bergman AJ; Dru J; Ho JZ; Jones AN; Staskiewicz SJ; Braun MP; Karanam B; Dean DC; Gendrano IN; Graves MW; Wagner JA; Krishna R
    Drug Metab Dispos; 2010 Mar; 38(3):474-83. PubMed ID: 20016053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human.
    Su H; Boulton DW; Barros A; Wang L; Cao K; Bonacorsi SJ; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2012 Jul; 40(7):1345-56. PubMed ID: 22496391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the non-nucleoside reverse transcriptase inhibitor lersivirine with its pyrazole and imidazole isomers.
    Jones LH; Allan G; Corbau R; Middleton DS; Mowbray CE; Newman SD; Phillips C; Webster R; Westby M
    Chem Biol Drug Des; 2011 May; 77(5):393-7. PubMed ID: 21352504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers.
    Bu HZ; Pool WF; Wu EY; Raber SR; Amantea MA; Shetty BV
    Drug Metab Dispos; 2004 Jul; 32(7):689-98. PubMed ID: 15205383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees.
    Riska PS; Joseph DP; Dinallo RM; Davidson WC; Keirns JJ; Hattox SE
    Drug Metab Dispos; 1999 Dec; 27(12):1434-47. PubMed ID: 10570025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
    Aouri M; Barcelo C; Ternon B; Cavassini M; Anagnostopoulos A; Yerly S; Hugues H; Vernazza P; Günthard HF; Buclin T; Telenti A; Rotger M; Decosterd LA;
    Drug Metab Dispos; 2016 Jan; 44(1):151-61. PubMed ID: 26553012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.